AU5917700A - Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections - Google Patents

Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections

Info

Publication number
AU5917700A
AU5917700A AU59177/00A AU5917700A AU5917700A AU 5917700 A AU5917700 A AU 5917700A AU 59177/00 A AU59177/00 A AU 59177/00A AU 5917700 A AU5917700 A AU 5917700A AU 5917700 A AU5917700 A AU 5917700A
Authority
AU
Australia
Prior art keywords
staphylococcal
staphylococcus
inhibitors
expression
protein function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59177/00A
Inventor
Barry K. Hurlburt
Tammy M. Rechtin
Mark S. Smeltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas filed Critical University of Arkansas
Publication of AU5917700A publication Critical patent/AU5917700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU59177/00A 1999-07-08 2000-07-07 Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections Abandoned AU5917700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14279399P 1999-07-08 1999-07-08
US60/142793 1999-07-08
PCT/US2000/018525 WO2001003686A2 (en) 1999-07-08 2000-07-07 Inhibitors of staphylococcus sara protein and their use in treating staphylococcal infections

Publications (1)

Publication Number Publication Date
AU5917700A true AU5917700A (en) 2001-01-30

Family

ID=22501308

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59177/00A Abandoned AU5917700A (en) 1999-07-08 2000-07-07 Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections

Country Status (2)

Country Link
AU (1) AU5917700A (en)
WO (1) WO2001003686A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258995B2 (en) * 2001-01-12 2007-08-21 Trustees Of Dartmouth College Compositions and methods for affecting virulence determinants in bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020121A (en) * 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
CA2280806A1 (en) * 1996-08-01 1998-08-20 California Institute Of Technology Inhibition of gene transcription by polyamide dna-binding ligands

Also Published As

Publication number Publication date
WO2001003686A2 (en) 2001-01-18
WO2001003686A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001286878A1 (en) Oxazolidinones and their use as antibacterial agents
AU2003290867A1 (en) Methods and products for treating staphylococcal infections
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
HUP0002662A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
AU2002219002A1 (en) Method and device for treating the surfaces of items
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU2003279526A1 (en) Identifying and treating vaginal infections
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU2002239485A1 (en) Methods for improved diagnosis and treatment of mycobacterial infections
ITMI950378A0 (en) ASSOCIATIONS OF LACTIC FERMENTS AND SACCAROMYCE LYSATES, THEIR THERAPEUTIC USE AND COMPOSITIONS THAT CONTAIN THEM
AU5622401A (en) Fabric treatment article and composition
AU2002353774A1 (en) Products and methods for treating microbial infections
AU2002228660A1 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
AU5917700A (en) Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections
AU2001262939A1 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AUPN907296A0 (en) Biocontrol agents for use in treatment of opportunistic infections
AU1923501A (en) Pyridinones to treat and prevent bacterial infections
PT1052991E (en) USING LOPERAMID FOR THE TREATMENT OF MICROBIAL INFECTIONS
AU2001279090A1 (en) Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
WO2004069196A3 (en) Novel compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase